^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
mRNA-5671
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Moderna
Drug class:
KRAS inhibitor
Related drugs:
Phase 1
Merck Sharp & Dohme LLC
Completed
Last update posted :
09/07/2022
Initiation :
06/26/2019
Primary completion :
08/25/2022
Completion :
08/25/2022
EGFR • KRAS • ALK • MSI
|
KRAS mutation • EGFR mutation • EGFR positive • HLA-A*11
|
Keytruda (pembrolizumab) • mRNA-5671
Share
